Pedersen 1995.

Methods	Study Design: Crossover RCT Randomisation:Random stated, method not described. Concealment of Allocation: Identical drug canisters administered in randomized order Double Blinding: Yes Withdrawals / dropouts: Described Adverse events: Not described Statistical analysis: Described Jadad Score: 3
Participants	Study site: multicentred No eligible: Not stated No randomised: 19 No completed: 18 Sex: Males:17(89%); Females 2(11%). Age: mean 11yrs Diagnostic criteria for asthma: Objective lung function Inclusion criteria: beta 2 use only, Symptoms> 3 days/week, >=20% bronchial reversibility post terbutaline or >= 20% fall in FEV1 post exercise test. Exclusion criteria: Bronchopulmonary disease other than asthma, oral prednisolone within 1 month before study Baseline severity of asthma: PC20 range: 22.5%‐76.5%; bronchial reversibility range: 26.5% ‐ 82.4%. mean duration of asthma: 7.5 yrs
Interventions	1: BUD 100mcg/day (50mcg bd) 2: BUD 200mcg/day (100mcg bd) 3: BUD 400mcg/day (200mcg bd) Delivery device: metered‐dose inhaler with spacer Duration of treatment: 4 weeks for each treatment period, no washout. Total treatment 12 weeks. Run in phase: 2 weeks Wash out phase: none Other: > 80% compliance
Outcomes	PEF & FEV1 post exercise testing, AHR (exercise), rescue medication, symptoms, urinary cortisol
Notes	no washout period between dose changes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Described as randomised; other information not available